Author(s):
1. Safia Ahmed:
Shaheed Benazir Bhutto Women University,Peshawar Khyber Pakhtunkhwa,Pakistan
Abstract:
Age-Related Storage Diseases are caused by catabolic insufficiency of our indigenous lysosomal enzymes which are unable to break down certain recalcitrant compounds generated because of normal body processes. When these compounds cross a threshold level at old age results in disease conditions like atherosclerosis and Age-Related Macular Degeneration (AMD). Atherosclerosis is affiliated with the build-up of cholesterol and its oxidation products markedly 7-ketocholesterol (7-KC) in the arterial linings while AMD is caused due to the aggregation of lipofuscin material, mainly the pyridinium bisretinoid A2E and Cycloretinal (all-trans retinal dimer). Medical bioremediation is a unique strategy of targeting these pathogenic compounds with an exogenous enzyme of microbial origin. Microbial strains were tested for biodegradation potential to biodegrade both bisretinoids and showed ability to biodegrade both A2E and Cycloretinal analysed visibly as well as by HPLC, ESI-MS and GCMS. ß-Ionone and 2,4 dimethylbenzaldehyde were identified as major degradation products of Cycloretinal while ß-ionone was identified as a major degradation product of A2E. 7-Ketocholesterol (7KC) is a major atherogenic compound causing atherosclerosis, which is a major contributor towards heart attack and stroke. Bacterial isolates, showing good catabolic activity towards 7-KC, were isolated using enrichment technique. Enzymes from these stains were cloned and produce for the application in bioremediation. This research work provides the key initial findings that can pave the way towards execution of the aspiring proposal called enzymatic degradation of lipofuscins (A2E and Cycloretinal) and oxysterol (7-KC), a new strategy for the treatment of Age Related Maccular Degeneration (AMD) and atherosclerosis. These encouraging results suggest further work to design a drug delivery system targeted at lysosomal compartments that can work in vivo. This enzyme may become future first choice biotechnology therapeutics for this currently untreatable disease.
Page(s):
0-0
DOI:
DOI not available
Published:
Journal: First International Conference on Revamped Scientific Outlook of 21st Century (Abstract Book), Volume: 0, Issue: 0, Year: 2022
Keywords:
bioremediation
,
Agerelated Diseases
,
Catabolic Enzymes
,
application
References:
References are not available for this document.
Citations
Citations are not available for this document.